These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1996556)

  • 21. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
    Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New variant of von Willebrand disease with defective binding to factor VIII.
    Nishino M; Girma JP; Rothschild C; Fressinaud E; Meyer D
    Blood; 1989 Oct; 74(5):1591-9. PubMed ID: 2506947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unique multimeric pattern of von Willebrand factor in a patient with a benign monoclonal gammopathy.
    López-Fernández MF; López-Berges C; Martín R; Nieto J; del Rio F; López-Borrasca A; Batlle J
    Scand J Haematol; 1986 Mar; 36(3):302-8. PubMed ID: 3486452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure.
    Gralnick HR; Williams SB; McKeown LP; Maisonneuve P; Jenneau C; Sultan Y
    Am J Hematol; 1987 Mar; 24(3):259-66. PubMed ID: 3493688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor.
    Cattaneo M; Moia M; Delle Valle P; Castellana P; Mannucci PM
    Blood; 1989 Nov; 74(6):1972-5. PubMed ID: 2508791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance.
    Castaman G; Tosetto A; Rodeghiero F
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():71-4. PubMed ID: 19630772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB; Mannucci PM; Lombardi R; Lattuada A; Colibretti ML; Dent JA; Zimmerman TS
    Am J Hematol; 1989 Dec; 32(4):287-93. PubMed ID: 2510503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtype.
    Mazurier C; Mannucci PM; Parquet-Gernez A; Goudemand M; Meyer D
    Am J Hematol; 1986 Jul; 22(3):301-11. PubMed ID: 3087159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration.
    de Jager NCB; Heijdra JM; Kieboom Q; Kruip MJHA; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2020 Oct; 120(10):1407-1416. PubMed ID: 32746466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.
    Sánchez-Luceros A; Meschengieser SS; Woods AI; Chuit R; Turdó K; Blanco A; Lazzari MA
    Thromb Haemost; 2010 Nov; 104(5):984-9. PubMed ID: 20886181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.
    Hommais A; Stépanian A; Fressinaud E; Mazurier C; Pouymayou K; Meyer D; Girma JP; Ribba AS
    Thromb Haemost; 2006 May; 95(5):776-81. PubMed ID: 16676067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.